Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates-Reference-Cited by-同舟云学术

Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates

Published:2018-05 Issue:5 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Snydman David R.¹,McDermott Laura A.¹,Jacobus Nilda V.¹,Kerstein Kathryn²,Grossman Trudy H.²,Sutcliffe Joyce A.²

Affiliation:

1. Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA

2. Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA

Abstract

ABSTRACT The novel fluorocycline antibiotic eravacycline is in development for use in the treatment of serious infections caused by susceptible and multidrug-resistant (MDR) aerobic and anaerobic Gram-negative and Gram-positive pathogens. Eravacycline and 11 comparator antibiotics were tested against recent anaerobic clinical isolates, including MDR Bacteroides spp. and Clostridium difficile . Eravacycline was potent in vitro against all the isolates tested, including strains with tetracycline-specific resistance determinants and MDR anaerobic pathogens resistant to carbapenems and/or β-lactam–β-lactamase inhibitor combinations.

Funder

Tetraphase Pharmaceuticals, Inc.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02206-17

Reference26 articles.

1. Lessons Learned from the Anaerobe Survey: Historical Perspective and Review of the Most Recent Data (2005–2007)

2. Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010–2012 with comparison to 2008–2009

3. U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin